Monday, April 9, 2012
Two measures being developed in
Washington could help offset the burden imposed by a requirement for extensive
cardiovascular risk assessment of drugs to treat obesity. Both could shift the paradigm
away from developing agents for the broader population.
In the first, FDA is
working with academics to define new endpoints and identify narrower groups of
patients most likely to benefit from weight loss treatments.